CYSLTR1 promotes adenoid hypertrophy by activating ERK1/2

Gao,Wenjie; Li,Jinying; Li,Quanheng; An,Shuhua

doi:10.3892/etm.2018.6282

August-2018 Volume 16 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2018 Volume 16 Issue 2

Full Size Image

Article

CYSLTR1 promotes adenoid hypertrophy by activating ERK1/2

Authors:
- Wenjie Gao
- Jinying Li
- Quanheng Li
- Shuhua An
View Affiliations / Copyright

Affiliations: Department of Pulmonary Diseases, Children's Hospital of Hebei Province, Shijiazhuang, Hebei 050011, P.R. China
Pages: 966-970
|
Published online on: June 8, 2018

https://doi.org/10.3892/etm.2018.6282
Expand metrics +

Abstract

Cysteinyl leukotriene receptor 1 (CYSLTR1) serves a pivotal role in allergic reactions, which is one of the main causes of adenoid hypertrophy. The present study aimed to investigate the function of CYSLT1 within adenoid hypertrophy. A total of 40 patients with adenoid hypertrophy were recruited between January 2014 and January 2016 at the Children's Hospital of Hebei Province, China. The patients were divided into either the mild‑moderate group or the severe group according to their disease severity. The expression of CYSLT1 in the adenoid tissue and whole blood of all patients and healthy controls was detected by reverse transcription‑quantitative polymerase chain reaction. Associations between the expression level of CYSLT1 and the clinical characteristics of patients were analyzed. Primary human adenoid epithelial cells (HAECs) with CYSLT1 knockdown and overexpression were constructed. The levels of extracellular signal‑regulated kinase (ERK)2 and phosphorylated‑ERK1/2 in adenoid tissue and HAECs were detected by western blot analysis. The expression of CYSLT1 in adenoid tissue and whole blood of all patients with adenoid hypertrophy was significantly higher compared with the healthy controls (P<0.05). In addition, the expression level of CYSLT1 was significantly higher in the severe group compared with the mild‑moderate group (P<0.05). The highest level of p‑ERK1/2 in adenoid tissue was observed in the severe group, followed by the mild‑moderate group and then the control group (P<0.05). CYSLT1 expression was positively associated with the severity of disease. CYSLT1 knockdown significantly decreased the level of p‑ERK1/2 in HAECs (P<0.05), while CYSLT1 overexpression significantly increased the level of p‑ERK1/2. It was concluded that CYSLT1 may contribute to the progression of adenoid hypertrophy by activating ERK1/2.

View Figures

View References

1	Koca CF, Erdem T and Bayındır T: The effect of adenoid hypertrophy on maxillofacial development: An objective photographic analysis. J Otolaryngol Head Neck Surg. 45:482016. View Article : Google Scholar : PubMed/NCBI
2	Raffat A and ul Hamid W: Cephalometric assessment of patients with adenoidal faces. J Pak Med Assoc. 59:747–752. 2009.PubMed/NCBI
3	Liu W, Zhou L, Zeng Q and Luo R: Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial. Sci Rep. 7:404252017. View Article : Google Scholar : PubMed/NCBI
4	Evcimik MF, Dogru M, Cirik AA and Nepesov MI: Adenoid hypertrophy in children with allergic disease and influential factors. Int J Pediatr Otorhinolaryngol. 79:694–697. 2015. View Article : Google Scholar : PubMed/NCBI
5	Honda T and Kabashima K: Leukotrienes as key mediators and amplifiers in allergic inflammation: Insights from the bench and clinic. Exp Dermatol. 23:95–96. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhu MH, Liang M, Wang ZJ, Shen Y, Wen HY, Zhai JM and Yang XB: Expression of CysLTR-1 and CysLTR-2 in adenoid tissues from children with adenoid hypertrophy. Zhongguo Dang Dai Er Ke Za Zhi. 17:159–163. 2015.(In Chinese). PubMed/NCBI
7	Al-juboori AN, Fadhil A and Sahib N: Adenoid hypertrophy in adult patients and its relation with allergy. Eur Sci J. 10:481–487. 2014.
8	Huang SW and Giannoni C: The risk of adenoid hypertrophy in children with allergic rhinitis. Ann Allergy Asthma Immunol. 87:350–355. 2001. View Article : Google Scholar : PubMed/NCBI
9	Henderson WR Jr, Chiang GK, Tien YT and Chi EY: Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 173:718–728. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY and Park HS: CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics. 8:1143–1150. 2007. View Article : Google Scholar : PubMed/NCBI
11	Roskoski R Jr: ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 66:105–143. 2012. View Article : Google Scholar : PubMed/NCBI
12	Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, Liu Q, Clements M, Zeng Z, O'Neill GP, et al: Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med. 163:226–233. 2001. View Article : Google Scholar : PubMed/NCBI
13	El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S and Benter IF: Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Br J Pharmacol. 166:1964–1976. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chen H, Xu X, Teng J, Cheng S, Bunjhoo H, Cao Y, Liu J, Xie J, Wang C, Xu Y and Xiong W: CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2. Int J Clin Exp Pathol. 8:6700–6707. 2015.PubMed/NCBI
15	Saw S and Arora N: PI3K and ERK1/2 kinase inhibition potentiate protease inhibitor to attenuate allergen induced Th2 immune response in mouse. Eur J Pharmacol. 776:176–184. 2016. View Article : Google Scholar : PubMed/NCBI
16	Paulucci BP, Pereira J, Picciarelli P, Levy D and Di Francesco RC: Expression of cysteinyl leukotriene receptor 1 and 2 (CysLTR1 and CysLTR2) in the lymphocytes of hyperplastic tonsils: Comparison between allergic and nonallergic snoring children. Int Forum Allergy Rhinol. 6:1151–1158. 2016. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

CYSLTR1 promotes adenoid hypertrophy by activating ERK1/2

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles